Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687207 | 0.83 | ILK (0.70) | ILK | |
| SCHEMBL687512 | 0.74 | ILK (1.00) | ILK | |
| SCHEMBL686711 | 0.74 | ILK (1.00) | ILK | |
| SCHEMBL6234898 | 0.74 | ILK (1.00) | ILK | |
| SCHEMBL686578 | 0.73 | ILK (1.00) | ILK | |
| SCHEMBL2165749 | 0.72 | ILK (0.66) | ILK | |
| SCHEMBL686525 | 0.71 | ILK (1.00) | ILK | |
| SCHEMBL2164352 | 0.71 | ILK (0.78) | ILK | |
| SCHEMBL686495 | 0.70 | ILK (1.00) | ILK | |
| SCHEMBL687383 | 0.70 | ILK (1.00) | ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | claimed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | claimed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | claimed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | claimed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | claimed |
| EP-1436332-A2 | METAL COMPLEX COMPOSITIONS AND THEIR USE AS CATALYSTS TO PRODUCE POLYDIENES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1401879-A1 | RANDOM OR BLOCK CO-OR TERPOLYMERS PRODUCED BY USING OF METAL COMPLEX CATALYSTS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2003033545-A2 | METAL COMPLEX COMPOSITIONS AND THEIR USE AS CATALYSTS TO PRODUCE POLYDIENES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2002090394-A1 | RANDOM OR BLOCK CO-OR TERPOLYMERS PRODUCED BY USING OF METAL COMPLEX CATALYSTS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2002-11-14 | — | — | WO | claimed |
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2267046-B1 | Process for homo- or copolymerization of conjugated olefines | STYRON EUROPE GMBH (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-20010012819-A1 | Ion exchanged aluminum-magnesium silicate or fluorinated magnesium silicate aerogels and catalyst supports therefrom | DOW CHEMICAL COMPANY, THE | 2001-08-09 | — | — | US | disclosed |
| US-6136993-A | CONTACTING IN GROUP 4 METAL COMPLEX OR ITS LEWIS BASE ADDUCT WITH METAL COMPLEX, RECOVERING RESULTING PRODUCT | THE DOW CHEMICAL COMPANY (US) | 2000-10-24 | — | — | US | disclosed |
| US-6127563-A | PREPARING BRIDGED GROUP 4 METAL COMPLEXES CONTAINING A NEUTRAL DIENE LIGAND STARTING FROM THE CORRESPONDING NOVEL, METAL DIENE CONTAINING COMPLEXES BY REACTION THEREOF WITH THE DIVALENT DERIVATIVE OF A BRIDGED BIDENTATE LIGAND COMPOUND | THE DOW CHEMICAL COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-6084115-A | METAL DIENE-CONTAINING COMPLEXES BY REACTION WITH THE DIVALENT DERIVATIVE OF A BRIDGED BIDENTATE LIGAND; METALLOCENES; RACEMIC ISOMER USED TO PREPARE ISOTACTIC POLYOLEFINS, E.G., CRYSTALLINE POLYPROPYLENE. | THE DOW CHEMICAL COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5959047-A | AN AROMATIC COMPLEX OF TITANIUM OR ZIRCONIUM OR HAFNIUM USED FOR POLYMERIZATION OF OLEFIN; | THE DOW CHEMICAL COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| US-5866704-A | 3-aryl substituted indenyl containing metal complexes and polymerization process | THE DOW CHEMICAL COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | ILK 2153/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | ILK 4705/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | ILK 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.